The potentiality of ICB2-5 as a potential subunit candidate for malaria vaccine development was based on findings that high levels of IgG3 antibodies against the N-terminus of Pv-MSP1 in asymptomatic individuals infected with Plasmodium vivax were associated with clinical protection and reduced risk of infection with Plasmodium vivax [42, 54]. The gene discussed is IGHG3; the disease is malaria.